HIV Nephropathy Diagnosis and Evaluation

Nephrology focuses on diagnosing and treating kidney diseases. The kidneys filter waste, balance fluids, regulate blood pressure, and manage acute and chronic conditions.

Diagnosis and Evaluation of HIV-Associated Nephropathy

Effective diagnosis and evaluation are the cornerstones of managing HIV-associated kidney disease, a condition that affects up to 30% of patients living with HIV worldwide. This page is designed for international patients and healthcare professionals seeking a clear, step‑by‑step overview of how Liv Hospital approaches the assessment of HIV nephropathy. From the first clinical encounter to advanced imaging and biopsy interpretation, we outline the evidence‑based protocols that guide treatment decisions. Understanding the full spectrum of diagnostic tools helps patients anticipate the process, ask informed questions, and collaborate confidently with their care team.

Our multidisciplinary team combines nephrology expertise with HIV specialist insight, ensuring that every test result is placed in the broader context of viral load, antiretroviral therapy, and overall health status. By the end of this guide, you will be familiar with the key investigations, their timing, and how they shape a personalized management plan.

Clinical Presentation and Initial Assessment

The first step in the diagnosis and evaluation of HIV‑associated nephropathy is a thorough clinical assessment. Patients often present with nonspecific symptoms such as fatigue, swelling of the lower extremities, or changes in urine output. However, early disease may be silent, making routine screening essential for those with a history of HIV infection.

History Taking

• Duration of HIV infection and current antiretroviral regimen.
• Recent changes in CD4 count and viral load.
• Presence of hypertension, diabetes, or other comorbidities.
• Medication adherence and potential nephrotoxic drug exposure.

Physical Examination

• Blood pressure measurement (hypertension is a common co‑factor).
• Assessment for peripheral edema, ascites, or pleural effusion.
• Evaluation of skin for rashes or lesions that may indicate opportunistic infections.

During the initial visit, clinicians also calculate the estimated glomerular filtration rate (eGFR) using serum creatinine and consider the patient's baseline renal function. A documented decline of >5 mL/min/1.73 m² per year often triggers further investigations.

Laboratory Investigations for HIV‑Associated Kidney Disease

Laboratory testing provides the quantitative backbone of the diagnosis and evaluation process. In addition to routine renal panels, specific assays help differentiate HIV‑related pathology from other causes of kidney injury.

Basic Renal Panel

• Serum creatinine and blood urea nitrogen (BUN).
• Electrolytes, including potassium and bicarbonate.
• eGFR calculated using the CKD‑EPI equation.

Urine Studies

• Spot urine protein‑to‑creatinine ratio (UPCR) or 24‑hour protein collection.
• Urinalysis for hematuria, casts, and tubular markers.
• Microalbuminuria testing for early glomerular damage.

HIV‑Specific Markers

• Current viral load (copies/mL) to assess virologic control.
• CD4+ T‑cell count for immune status.
• Serum antiretroviral drug levels when nephrotoxicity is suspected.

Additional serologic tests may be ordered to exclude co‑existing infections such as hepatitis B/C or syphilis, which can also affect renal function. The combination of proteinuria measurement, eGFR trend, and HIV disease activity forms a comprehensive picture that guides the next diagnostic steps.

Imaging Techniques and Their Role in Diagnosis

While laboratory data highlight functional impairment, imaging studies visualize structural changes, completing the diagnosis and evaluation of HIV‑related kidney disease. Non‑invasive modalities are preferred initially, reserving more detailed examinations for ambiguous cases.

Renal Ultrasound

• Assesses kidney size, cortical thickness, and presence of hydronephrosis.
• Detects renal cysts or obstructive uropathy that may mimic nephropathy.

Doppler Ultrasound

• Evaluates renal arterial resistive index, which can be elevated in chronic kidney disease.
• Helps differentiate between vascular and parenchymal causes of dysfunction.

Advanced Imaging (CT or MRI)

• Contrast‑enhanced CT provides detailed anatomy but requires careful consideration of nephrotoxic contrast agents.
• Magnetic resonance imaging (MRI) with gadolinium‑based agents is an alternative for patients with severe renal impairment, using low‑dose protocols.

Imaging findings are summarized in the table below, illustrating typical patterns seen in HIV‑associated nephropathy versus other renal pathologies.

Kidney Biopsy: Indications, Procedure, and Interpretation

When non‑invasive assessments are inconclusive, a renal biopsy becomes essential for definitive diagnosis and evaluation. The procedure provides histopathologic insight that distinguishes HIV‑associated focal segmental glomerulosclerosis (FSGS) from other glomerular diseases.

Indications for Biopsy

• Proteinuria >1 g/day with unexplained rapid eGFR decline.
• Unusual urinary sediment (e.g., active casts) not explained by infection.
• Failure to respond to optimized antiretroviral therapy.

Procedure Overview

• Performed percutaneously under real‑time ultrasound guidance.
• Local anesthesia with optional conscious sedation.
• Typically 2–3 cores are obtained for light microscopy, immunofluorescence, and electron microscopy.

Pathologic Patterns

Staging and Prognostic Evaluation

After completing the comprehensive diagnosis and evaluation, clinicians stage the disease to predict outcomes and guide follow‑up intensity. Staging combines eGFR categories, proteinuria levels, and HIV disease activity.

Kidney Disease Staging (KDIGO)

• G1–G5 based on eGFR ranges (≥90 to <15 mL/min/1.73 m²).
• A1–A3 based on albuminuria (<30 mg/g to >300 mg/g).

HIV‑Related Risk Stratification

• Controlled viral load (<50 copies/mL) and CD4 >350 cells/µL confer better renal prognosis.
• Persistent viremia or CD4 <200 cells/µL are associated with faster progression.

The combined staging matrix is illustrated below, helping patients and providers visualize risk and schedule monitoring intervals.

Multidisciplinary Approach to Ongoing Evaluation

HIV‑associated nephropathy demands continuous reassessment. A multidisciplinary team—including nephrologists, infectious disease specialists, pharmacists, dietitians, and mental‑health professionals—ensures that the diagnosis and evaluation remains current as the patient’s clinical status evolves.

Follow‑Up Schedule

• Every 3–6 months: eGFR, UPCR, viral load, CD4 count.
• Annual renal ultrasound to monitor structural changes.
• Prompt reassessment after any change in antiretroviral regimen.

Therapeutic Adjustments Based on Evaluation

• Switch to less nephrotoxic antiretrovirals if renal function declines.
• Introduce ACE inhibitors or ARBs for proteinuria reduction.
• Consider referral for renal replacement therapy when eGFR <15 mL/min/1.73 m².

Patient education is integral; individuals are taught to recognize early signs of worsening kidney function and to maintain adherence to both HIV and renal medications. The coordinated care model at Liv Hospital streamlines communication across specialties, reducing delays in intervention.